Ocera Therapeutics Inc

Ocera Therapeutics — Tranzyme — Merger or Acquisition (April 2013)

28 slides from Ocera Therapeutics's merger presentation, Apr 24, 2013

  1. Slide 1: Tranzyme and Ocera: A Synergistic Merger Opportunity

    Tranzyme and Ocera A Synergistic Merger Opportunity April 2013

  2. Slide 2: Forward-Looking Statements / Additional Information

    Forward-Looking Statements / Additional Information Cautionary Note Regarding Forward-Looking Statements Certain statements in this communication regarding the proposed merger and other contemplated transactions (including statements relating to satisfaction of the conditions to and consummation of

  3. Slide 3: Forward-Looking Statements / Additional Information

    Forward-Looking Statements / Additional Information risks resulting from unforeseen side effects; risk that the market for the combined company’s products may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs

  4. Slide 4: Forward-Looking Statements / Additional Information

    Forward-Looking Statements / Additional Information Each of Tranzyme’s board of directors, John H. Johnson, George B. Abercrombie, Jean-Paul Castaigne, Vipin K. Garg, Anne M. VanLent, and Alex Zisson; Tranzyme’s executive officers, Vipin K. Garg (President and Chief Executive Officer), Franck Rousse

  5. Slide 5: Forward-Looking Statements / Additional Information

    Forward-Looking Statements / Additional Information Nina Kjellson, a director of Ocera, is a partner in InterWest Partners IX, LP (“InterWest”), a stockholder of Ocera. InterWest beneficially owns in the aggregate approximately 3,530,891 shares of Ocera stock after giving effect to the exercise of c

  6. Slide 6: Forward-Looking Statements / Additional Information

    Forward-Looking Statements / Additional Information This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. A definitive proxy statement and a proxy card will be filed with the SEC and will be mailed to

  7. Slide 7: History: Significant potential for value creation in combining Tranzyme-Ocera

    History Significant potential for value creation in combining Tranzyme-Ocera Tranzyme Board conducted an extensive exploration of strategic alternatives; Reviewed over 100 life science companies Tranzyme Board evaluated other alternatives and determined they did not maximize value for stockholders

  8. Slide 8: Transaction Overview

    Transaction Overview Terms All stock transaction Stockholders of Ocera will receive 1.538 shares for each share held(1) Equity value of the combined company of approximately $52.4 million(2)(3) Intended to qualify as a tax-free reorganization Ownership at Closing 27.4% Tranzyme; 72.6% Ocera(1)(3) Co

  9. Slide 9: Strong Combined Management and Clinical Teams

    Strong Combined Management and Clinical Teams Strong combined management team with significant experience: Linda Grais, MD, President and Chief Executive Officer Physician, biotechnology entrepreneur (SGX Pharmaceuticals) and investor (InterWest Partners) Appointed CEO of Ocera June 2012; joined Boa

  10. Slide 10: Combined Pipeline

    Combined Pipeline * Zysa™ has CE Mark approval as medical device in EU for d-IBS; in discussions with EU marketing partner. Currently no plans to develop further in US **MATCH technology/platform – Proprietary drug discovery and medicinal chemistry platform that provides potential for future develop

  11. Slide 11: Clinical Stage Orphan Disease Asset, Multiple Value Creating Milestones

    Clinical Stage Orphan Disease Asset Multiple Value Creating Milestones Large Commercial Opportunity with Limited Competition Differentiated product for severe disease with high unmet need Novel ammonia scavenger with clear and simple mechanism of action Orphan and Fast Track designations Phase 2b re

  12. Slide 12: Orphan Indications: Rapid Development and Commercialization Path

    Patients with significant unmet medical needs and a lack of effective therapies Identifiable patient populations treated by a concentrated physician audience Accelerated and less expensive development Small clinical trials Phase 2b data will provide meaningful indicators of later success Unmet medic

  13. Slide 13: Two Drug Candidates with Compelling Value Propositions

    Two Drug Candidates with Compelling Value Propositions Candidate OCR-002 IV OCR-002 Oral Indication Treatment of acute, life-threatening hepatic encephalopathy Maintenance of chronic hepatic encephalopathy remission Commercial Rights All rights retained All rights retained Value Proposition Unmet me

  14. Slide 14: Liver Disease Leads to Elevated Ammonia

    Liver Disease Leads to Elevated Ammonia Diseased Liver Adapted from Jalan 2009 Gastroenterology Healthy Liver

  15. Slide 15: OCR-002: A Novel Ammonia Scavenger

    OCR-002: A Novel Ammonia Scavenger Mechanism of action well-characterized based on synergy of ornithine and phenylacetate Dual mechanism leads to greater potency Up-regulates extra-hepatic ammonia elimination pathways Increases urinary output of ammonia in form of phenylacetylglutamine or PAGN Lower

  16. Slide 16: OCR-002: Development Strategy

    OCR-002: Development Strategy Focus on faster-to-market acute care IV opportunity Targeted study in IV Phase 2b for HE Objective endpoints (ammonia and clinical neurocognitive status) Short treatment course (5 days) No competing therapies Leverage known/expected safety and efficacy profile Establish

  17. Slide 17: OCR-002: IV Clinical Development Summary

    Phase 1 Phase 2 Phase 3 Completed, n=91 Ph 2a Upper GI Bleed (UGIB) Enrolling, n=48 Ph 2b Acute HE Planned, n=200 Ph 2a Acute Liver Injury/Failure (ALF) Enrolling, n=24 Ph 3 Acute HE Planned, 2 trials, n=400 (200 x 2)* Ph 1/2a STATUS OCR-002: IV Clinical Development Summary *potential to consolidate

  18. Slide 18: Double Blind IV Phase 2a Enrolling - Upper GI Bleed in Cirrhosis

    Primary endpoint: reduction in plasma ammonia Secondary endpoints: safety, PK/PD, West Haven, neurocognition, infection rates Randomized, double-blind, safety and efficacy study in 3 sites in Spain 25-35% develop acute HE with increased mortality and risk of future HE events Inclusion criteria: post

  19. Slide 19: IV Phase 2a: UGIB - Status

    IV Phase 2a: UGIB - Status Open label safety cohort completed (n=10) OCR-002 well tolerated at target dose of 10g/24h Ammonia levels normalized from baseline by 36 hrs (P<0.05) No incidence of acute HE on OCR-002 (usual incidence 25-35%) Randomized, double blind phase currently enrolling – 15 patien

  20. Slide 20: IV Phase 2a: UGIB - Open Label Cohort Results

    IV Phase 2a: UGIB - Open Label Cohort Results Time (h) Mean Plasma Ammonia ( m M) * * * * P < 0.05 Ammonia normalized within 36h (ISHEN/AASLD 2012) * OP 10g/24h 3.3g 1.65g Infusion stopped Same site, matched historical control (n=15); enrolled within the 5 months prior to study start (n=10) Normal *

  21. Slide 21: IV Phase 2a: Acute Liver Failure (ALF) Study

    IV Phase 2a: Acute Liver Failure (ALF) Study Trial supported by NIH through Acute Liver Failure Study Group ALF patients: Ultra orphan population (2000/yr) Often young, otherwise healthy 50% Acetaminophen overdose, and other acute liver shocks 30% mortality, primarily due to cerebral herniation as a

  22. Slide 22: Planned IV Phase 2b Study: Acute Hepatic Encephalopathy

    Planned IV Phase 2b Study: Acute Hepatic Encephalopathy (HE) Background Cirrhotic patients hospitalized with hepatic encephalopathy – aim to show clinical improvement in encephalopathy along with ammonia reduction Statistically powered to show ammonia in the first 50 patients Hospitalized Cirrhotics

  23. Slide 23: Multiple Value Creating Milestones

    Multiple Value Creating Milestones Q1 2014 Phase 2a UGIB Data Q4 2013 Initiate IV Phase 2b Q3 2014 STOP-ALF Data Q3 2014 Interim Phase 2b Data YE 2014 Phase 2b Completion

  24. Slide 24: Comparative Product Profile Between OCR-002 and Standard of Care

    Comparative Product Profile Between OCR-002 and Standard of Care for Acute HE Product Formulation(s) Mechanism of Action Dosage & Route of Administration Comments liquid water-soluble powder Flushes out the gut by inducing osmotic diarrhea Four times daily; NG tube and enema Slow onset of efficacy I

  25. Slide 25: Summary: OCR-002 IV Opportunity

    Summary: OCR-002 IV Opportunity Liver cirrhosis is a large, and growing market due to hepatitis, alcohol, obesity High percentage of cirrhotic patients develop HE and require hospitalization ~150k applicable patients in the US Market Limited treatment options for acute HE in hospital and no IV formu

  26. Slide 26: OCR-002: Oral Product

    OCR-002: Oral Product Indication: Maintenance of remission of HE Benefits: Oral solid dosage form (tablets) No sodium; non-antibiotic Promotes recycling of glutamine (building block and energy source) Requires completion of preclinical tox and product development Phase 3 program based on precedent c

  27. Slide 27: Tranzyme Conducted an Extensive and Thorough Strategic Alternative Review Process

    Tranzyme Conducted an Extensive and Thorough Strategic Alternative Review Process December 2012: While Tranzyme management evaluated internal development opportunities, Tranzyme Board resolved to, concurrently, engage Stifel to explore strategic alternatives to maximize stockholder value including:

  28. Slide 28: Tranzyme and Ocera: A Synergistic Merger Opportunity

    Tranzyme and Ocera A Synergistic Merger Opportunity April 2013

Tranzyme — Merger or Acquisition (April 2013) on 6ix